NeoGenomics Reports Preliminary FY25 Revenue of $727M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Reports preliminary FY25 revenue $727M, consensus $725.09M. "Our preliminary fourth quarter revenue reflects our ongoing commitment to being the cancer testing 'partner of choice' to pathologists and oncologists in the community setting, where approximately 80% of cancer care is delivered today," stated Tony Zook, CEO of NeoGenomics. "With one of the broadest oncology test menus in the industry, including the latest innovations in therapy selection and recurrence monitoring, I believe we are very well positioned to continue on our trajectory of double-digit revenue growth while helping improve outcomes for cancer patients across the U.S."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 14.00 USD with a low forecast of 12.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 12.380
Low
12.00
Averages
14.00
High
16.00
Current: 12.380
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeoGenomics to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: NeoGenomics will announce its fourth quarter and full year 2025 financial results before the U.S. market opens on February 17, 2026, which is expected to provide investors with critical financial data and business highlights.
- Management Conference Call: The company's management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights, enhancing transparency and engaging with investors.
- Webcast Access: Investors can access the live webcast through the Investor Relations section of the company’s website, with a replay available shortly after the call, ensuring that those unable to attend live can still obtain the information.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services to oncologists and hospital systems, further solidifying its leadership in the oncology diagnostics field.
Continue Reading
NeoGenomics (NEO) Projects $727 Million Revenue for 2025 with CFO Transition
- Revenue Growth Outlook: NeoGenomics anticipates approximately $190 million in revenue for Q4 2025, reflecting an 11% year-over-year increase, indicating sustained demand in the cancer testing sector and reinforcing its position as the partner of choice.
- Annual Revenue Projection: The company expects full-year 2025 revenue to reach $727 million, representing a 10% year-over-year growth, showcasing its ongoing potential in precision medicine, particularly in innovative cancer treatment testing.
- Executive Transition: The company announced a CFO succession plan with Abhishek Jain set to assume the CFO role on March 2, 2026, while current CFO Jeff Sherman transitions to Executive Vice President, ensuring a smooth leadership transition to support future growth strategies.
- Financial Stability: Jain's extensive experience in the life sciences sector is expected to enhance NeoGenomics' financial discipline and operational efficiency, further driving long-term value creation in the advanced cancer testing market.
Continue Reading